Raymond Hohl
University Professor of Oncology; Professor of Pharmacology

-
400 University Drive
Hershey, PA - rjh35@psu.edu
- 717-531-6585
Publication Tags
Neoplasms T Lymphocytes Therapeutics Cell Line Acute Myeloid Leukemia Pharmacology Glioblastoma 5' Methylschweinfurthin G Cyclophosphamide Transplants Proteins Radiation Radiotherapy Cholesterol Parkinson Disease Immunoglobulin Domains Up Regulation Appalachian Region Myeloid Derived Suppressor Cells Immunogenic Cell Death Antipsychotic Agents Prostatic Neoplasms Tissue Donors Names TemozolomideMost Recent Publications
RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins
J. S. Weissenrieder, J. D. Weissenkampen, J. L. Reed, M. V. Green, C. Zheng, J. D. Neighbors, D. J. Liu, Raymond J. Hohl, 2022, Scientific Reports
Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide
Neal Shah, J Cioccio, Kevin Rakszawski, H Zheng, Myles Nickolich, Seema Naik, Baldeep Wirk, Witold Rybka, Christopher Ehmann, W Ehmann, Brook Silar, Caitlin Vajdic, Joseph Mierski, S Zhou, Hiroko Shike, Robert Greiner, Valerie Brown, Raymond Hohl, David Claxton, Shin Mineishi, Kentaro Minagawa, Leonard Tuanquin, 2022, Leukemia Research
Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma
Emily J. Koubek, Jillian S. Weissenrieder, Luz E. Ortiz, Nnenna Nwogu, Alexander M. Pham, J. Dylan Weissenkampen, Jessie L. Reed, Jeffrey D. Neighbors, Raymond J. Hohl, Hyun Jin Kwun, 2022, Viruses
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant
Chenchen Zhao, Matthew Bartock, Bei Jia, Neal Shah, David F. Claxton, Baldeep Wirk, Kevin L. Rakszawski, Myles S. Nickolich, S Naik, Witold B. Rybka, Ehmann WCC, W. Christopher C. Ehmann, Raymond J. Hohl, Jessica Valentin, Michelle Bernas-Peterson, Emily Gerber, Michele Zimmerman, Joseph Mierski, Shin Mineishi, Hong Zheng, 2022, Journal of Hematology and Oncology on p. 64
Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis
Joseph Cioccio, Kevin Rakszawski, Hong Zheng, Myles Nickolich, Seema Naik, Baldeep Wirk, Witold Rybka, Christopher Ehmann, Brooke Silar, Caitlin Vajdic, Neal Shah, Leonard Tuanquin, Robert Greiner, Valerie Brown, Raymond Hohl, David Claxton, Shin Mineishi, Kentaro Minagawa, Hiroko Shike, 2022, Annals of Hematology
Schweinfurthin induces ICD without ER stress and caspase activation
Ruoheng Zhang, J. D. Neighbors, T. D. Schell, R. J. Hohl, 2022, OncoImmunology
Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells
Barbara Manfredi, Jeffrey D. Neighbors, Raymond J. Hohl, 2022, Pharmacology on p. 510-523
Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D<sub>2</sub> receptor-dependent, manner
Jillian S. Weissenrieder, Jessie L. Reed, George Lucian Moldovan, Martin T. Johnson, Mohamed Trebak, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2021, Pharmacology Research and Perspectives
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia
Hong Zheng, Shin Mineishi, David Claxton, Junjia Zhu, Chenchen Zhao, Bei Jia, W. Christopher Ehmann, Witold B. Rybka, Seema Naik, Natthapol Songdej, Joseph J. Drabick, Raymond J. Hohl, 2021, American Journal of Hematology on p. E46-E50
Prostate cancer incidence and aggressiveness in appalachia versus non-appalachia populations in Pennsylvania by urban-rural regions, 2004–2014
Alicia C. McDonald, Emily Wasserman, Eugene J. Lengerich, Jay D. Raman, Nathaniel R. Geyer, Raymond J. Hohl, Ming Wang, 2020, Cancer Epidemiology Biomarkers and Prevention on p. 1365-1373
Most-Cited Papers
O<sub>2</sub><sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P. Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Shultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 487-500.e8
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Liru Wang, Bei Jia, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng, 2018, OncoImmunology
Erratum: O<sub>2</sub> <sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate (Cancer Cell (2017) 32 (2)(268) (S1535610817300624) (10.1016/j.ccell.2017.02.018))
Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P.Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Schultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 268
Cancer and the dopamine D<sub>2</sub> receptor: A pharmacological perspective
Jillian S. Weissenrieder, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2019, Journal of Pharmacology and Experimental Therapeutics on p. 111-126
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng, Hong Zheng, 2017, Journal of Hematology and Oncology on p. 124
First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma
Bryan G. Allen, Kellie L. Bodeker, Mark C. Smith, Varun Monga, Sonia Sandhu, Raymond Hohl, Thomas Carlisle, Heather Brown, Nancy Hollenbeck, Sandy Vollstedt, Jeremy D. Greenlee, Matthew A. Howard, Kranti A. Mapuskar, Steven N. Seyedin, Joseph M. Caster, Karra A. Jones, Joseph J. Cullen, Daniel Berg, Brett A. Wagner, Garry R. Buettner, Mindi J. TenNapel, Brian J. Smith, Douglas R. Spitz, John M. Buatti, 2019, Clinical Cancer Research on p. 6590-6597
Eomes<sup>+</sup>T-bet<sup>low</sup> CD8<sup>+</sup> T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia
Bei Jia, Chenchen Zhao, Kevin L. Rakszawski, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Ming Wang, Hiroko Shike, Michael G. Bayerl, Jeffrey M. Sivik, Todd D. Schell, Joseph J. Drabick, Raymond J. Hohl, Hong Zheng, 2019, Cancer Research on p. 1635-1645
Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients
Bei Jia, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Syed Rizvi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, 2018, Blood Cancer Journal
Brain cholesterol metabolism and Parkinson's disease
Xuemei Huang, N Sterling, Guangwei Du, Dongxiao Sun, C Stetter, Lan Kong, Yusheng Zhu, Jeffery Neighbors, Mechelle M. Lewis, H Chen, Raymond J. Hohl, Richard B. Mailman, 2019, Movement Disorders on p. 386-395
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
L. Sokol, L. Cripe, H. Kantarjian, M. A. Sekeres, S. Parmar, P. Greenberg, S. L. Goldberg, V. Bhushan, J. Shammo, R. Hohl, A. Verma, G. Garcia-Manero, Y. P. Li, A. Lowe, J. Zhu, A. F. List, 2013, Leukemia on p. 977-980